早期乳腺癌术中电子线瘤床加量联合大分割全乳放疗的毒性与美容效果:HIOB前瞻性多中心试验首次结果
HIOB试验评估低中危早期乳腺癌保乳术后术中电子线加量(IOERT 11.1 Gy)联合大分割全乳放疗(40.5 Gy/15次)的急性和晚期毒性及美容效果。中位随访45个月,急性毒性CTCAE 0/1级在HWBI结束时为91%、4周后为92%;晚期毒性LENT-SOMA 0/1级在4/5个月为92.7%,6年升至96.5%;美容效果主观评估优良率86%、客观评估74%,此后无损害。结论认为该方案短期/中期耐受性极佳,术后3年美容外观未受损。
要点
- IOERT 11.1 Gy加量联合HWBI 40.5 Gy/15次方案急性和晚期毒性均以0/1级为主。
- HWBI结束时急性CTCAE 0/1级占91%,4周后占92%。
- 晚期LENT-SOMA 0/1级4/5个月为92.7%,6年升至96.5%。
核心结论
- Boost-IOERT联合HWBI方案在短期和中期评估中急性和晚期耐受性极佳,术后3年美容外观未受损。
研究设计与样本
- 前瞻性多中心单臂试验(NCT01343459),2011年启动,纳入低中危早期乳腺癌保乳术后患者。
- 治疗方案为保乳手术、IOERT 11.1 Gy加量、HWBI 40.5 Gy分15次。
- 627例合格患者中排除44例,最终分析583例,中位随访45个月(范围0-74)。
- 5年同侧乳腺复发率按3个年龄组(35-40岁、41-50岁、>50岁)通过序贯比例检验与已发表最佳证据进行基准比较。
- 急性和晚期毒性及美容效果采用经验证的评分系统评估。
主要发现
- 急性毒性CTCAE 0/1级在HWBI结束时为91%,4周后为92%。
- 晚期毒性LENT-SOMA 0/1级(均值,范围)在4/5个月为92.7%(89-97.3),HWBI后6年升至96.5%(91-100)。
- HWBI前伤口愈合后基线美容效果主观(患者)评估优良率为86%,客观(医生)评估为74%,此后无损害。
关键数值与推荐
- IOERT加量剂量为11.1 Gy,HWBI剂量为40.5 Gy分15次。
- 急性毒性采用CTCAE评分,晚期毒性采用LENT-SOMA标准。
- 美容效果采用主观(患者)和客观(医生)评估,基线优良率分别为86%和74%。
临床怎么用
- 对于低中危早期乳腺癌保乳术后患者,可考虑IOERT瘤床加量联合大分割全乳放疗方案。
- 该方案短期和中期急性和晚期毒性低,美容效果在3年随访内未见损害。
局限性
- 单臂设计,5年同侧乳腺复发率通过序贯比例检验与外部证据基准比较,非随机对照。
- 中位随访45个月,长期(>6年)毒性和美容效果数据有限。
- 全文未报告美容效果评估的具体随访时间点及统计比较细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To assess the role of intraoperative radiation with electrons (IOERT) as tumor bed boost followed by hypofractionated whole breast irradiation (HWBI) after breast conserving surgery (BCS) of patients with low to intermediate risk breast cancer focusing on acute/late toxicity and cosmetic outcome. MATERIAL AND METHODS: In 2011, a prospective multicenter trial (NCT01343459) was started. Treatment consisted of BCS, IOERT (11.1 Gy) and HWBI (40.5 Gy in 15 fractions). In a single-arm design, 5-year IBR-rates are benchmarked by a sequential ratio test (SQRT) against best published evidences in 3 age groups (35-40 y, 41-50 y, >50 y). Acute/late toxicity and cosmesis were evaluated by validated scorings systems. RESULTS: Of 627 eligible patients, 44 were excluded, leaving 583 to analyze. After a median follow-up (FUP) of 45 months (range 0-74), for acute effects CTCAE-score 0/1 was noted in 91% (end of HWBI) and 92% (4 weeks later), respectively. Late toxicity Grading 0/1 (mean values, ranges) by LENT-SOMA criteria were observed in 92.7% (89-97.3) at 4/5 months, rising to 96.5% (91-100) at 6 years post HWBI. Baseline cosmesis after wound healing prior to HWBI was scored as excellent/good in 86% of cases by subjective (patient) and in 74% by objective (doctor) assessment with no impairment thereafter. CONCLUSIONS: Acute and late treatment tolerance of a combined Boost-IOERT/HWBI regimen is excellent in short/mid-term assessment. Postoperative cosmetic appearance is not impaired after 3 years FUP.
引用
- Fastner G, Reitsamer R, Urbański B, et al. Toxicity and cosmetic outcome after hypofractionated whole breast irradiation and boost-IOERT in early stage breast cancer (HIOB): First results of a prospective multicenter trial (NCT01343459). Radiother Oncol. 2020. PMID: 32151790. doi:10.1016/j.radonc.2020.02.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。